CNBX Pharmaceuticals Inc.
CNBX
$0.002
$0.000.00%
OTC PK
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0.00 | -- | 40.60K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 0.00 | -- | 40.60K |
| Cost of Revenue | -- | -- | -- | -- | 6.20K |
| Gross Profit | -- | -- | 0.00 | -- | 34.40K |
| SG&A Expenses | 64.70K | 36.80K | 126.50K | 109.40K | 133.60K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.70K | 36.80K | 52.50K | 152.30K | 247.10K |
| Operating Income | -64.70K | -36.80K | -52.50K | -152.30K | -206.40K |
| Income Before Tax | -69.80K | -34.40K | -60.60K | -130.60K | -325.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -69.80K | -34.40K | -60.60K | -130.60K | -325.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.80K | -34.40K | -60.60K | -130.60K | -325.50K |
| EBIT | -64.70K | -36.80K | -52.50K | -152.30K | -206.40K |
| EBITDA | -46.70K | -18.80K | -52.50K | -152.30K | -173.60K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 32.10M | 31.11M | 31.10M | 31.11M | 30.99M |
| Average Diluted Shares Outstanding | 32.10M | 31.11M | 31.10M | 31.11M | 30.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |